Bachem Well Positioned in Demanding Market

Bachem Group (SIX: BANB) an independent company recognised globally as a manufacture of the highest quality of biochemicals and pharmaceutical drug products has published its half year report. Bachem are very well positioned in this demanding market and are on target to increase sales growth for the rest of the year. Bachem has announced sales of 76.2 million CHF for the first half of 2012. Sales were slightly lower than in the prior year period, down 1.7% in local currency and down 1.9% in CHF, the reporting currency. Compared to the second half of 2011, however, Bachem generated about 8 million CHF more in sales (+11.8%).

About Bachem
Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries.

It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio.

Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

Bachem. Pioneering Partner for Peptides

For more information or to discuss the half year report please contact us directly.

Resources

Click on Bachems News to see latest News & Events.